School of Pharmacy, Chengdu University of Traditional Chinese medicine.
Chengdu Third People's Hospital.
Medicine (Baltimore). 2021 Jan 8;100(1):e24198. doi: 10.1097/MD.0000000000024198.
With the outbreak of novel coronavirus, the treatment of respiratory diseases has been promoted. In particular, many traditional Chinese medicines, including Chinese patent medicines, have been found to be effective in the treatment of respiratory illness in China. chronic obstructive pulmonary disease (COPD) is one of most common respiratory condition. It is predicted that COPD will be become the third frequent cause of death by 2030. The aim of this study is to assess the efficacy and safety of Shufeng Jiedu Capsule in the treatment of acute exacerbations of chronic obstructive pulmonary disease (AECOPD).
According to the search strategy, randomized controlled trials (RCTs) of Shufeng Jiedu Capsule in the treatment of AECOPD were obtained from Cochrane Library, MEDLINE, Embase, CNKI, VIP, CBM, and WANGFANG. Studies were screened according to inclusion and exclusion criteria, and the Cochrane risk bias assessment tool was used to assess the quality of the study. Meta-analysis was performed using Revman 5.4 software. Finally, the evidence level of the results will be evaluated.
The purpose of this study was to evaluate the efficacy and safety of Shufeng Jiedu Capsule in the treatment of AECOPD, and to provide basis for clinical rational drug use.
Our research results of this study could provide reference for clinical decision-making and guiding development in the future COPD patient.
INPLASY2020120062.
随着新型冠状病毒的爆发，呼吸系统疾病的治疗得到了推动。特别是在中国，许多中药，包括中成药，被发现对呼吸系统疾病的治疗有效。慢性阻塞性肺疾病（COPD）是最常见的呼吸系统疾病之一。预计到 2030 年，COPD 将成为第三大常见死因。本研究旨在评估疏风解毒胶囊治疗慢性阻塞性肺疾病急性加重（AECOPD）的疗效和安全性。
根据检索策略，从 Cochrane 图书馆、MEDLINE、Embase、CNKI、VIP、CBM 和 WANGFANG 中获取疏风解毒胶囊治疗 AECOPD 的随机对照试验（RCT）。根据纳入和排除标准筛选研究，并使用 Cochrane 风险偏倚评估工具评估研究质量。使用 Revman 5.4 软件进行荟萃分析。最后，评估结果的证据水平。
本研究旨在评估疏风解毒胶囊治疗 AECOPD 的疗效和安全性，为临床合理用药提供依据。
本研究的研究结果可为未来 COPD 患者的临床决策和指导开发提供参考。
INPLASY 注册号：INPLASY2020120062。
